ASH 2022 | First-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, describes the mechanism of action of huCART19-IL18, a 4th generation autologous CAR-T cell product, and outlines findings from a first-in-human trial investigating the efficacy of this agent in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) (NCT04684563). Results from this study so far have been encouraging, with no unexpected toxicities being recorded and some patients already achieving complete response. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
TG: Research Funding; SEAGEN: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Merck: Research Funding; Incyte: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genmab: Consultancy; BMS: Consultancy, Research Funding; Atara: Consultancy; Astra Zeneca: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity’s Board of Directors or advisory committees, Research Funding; ADCT: Consultancy.
